Revenue Growth
Total revenue for Q1 2025 was $270 million, representing an increase of $24 million over Q1 2024.
Recurring Revenue Achievement
There was notable growth in recurring revenue, with contributions from the XT Amplify program and SaaS and Expert Services.
Non-GAAP Earnings Improvement
Non-GAAP earnings per share for Q1 2025 were $0.26, compared to $0.03 in the same period last year.
Customer Wins and Partnerships
Significant customer wins across various regions, with health systems investing in Omnicell solutions to improve efficiency and safety.
Cash Flow and Liquidity
Free cash flow of $10 million during Q1 2025, with cash and cash equivalents rising to $387 million from $369 million in the previous quarter.